ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

July - September 2005, Volume 1, Issue 3
General Endocrinology


Mihaescu G, Olinescu R, Oancea F

Metabolic syndrome may be improved following a long-time administration of a nutritive supplement containing embryonary peptides

Acta Endo (Buc) 2005, 1 (3): 263-270
doi: 10.4183/aeb.2005.263

Metabolic Syndrome (MS) is a polymorph disease with a high frequency especially in older age. Any randomized study with nonhospitalized subjects might include those bearing MS, that greatly influenced the final results. Eighty subjects aged 50-75 years (38 men and 42 women) had consumed daily 4 caps of purified Embryonary Peptides (EP) for 60 days. The samples of blood from each subject were obtained before and after administration. Therefore, each subject was his own control. In all subjects, after administration, regardless of the MS presence, total cholesterol and LDL-cholesterol had decreased approximately 30 % as compared with the initial values. Significant decreases of insulin and cortisol were also observed, but associated with modifications of PSA, CEA and IGF-l. The magnitude of these changes was lower in subjects with MS. The long-lasting modifications induced by EP seem to have an adaptive-regulatory character, affecting the lipid metabolism (already modified in MS), as well as some pathways from steroid biosynthesis. Thus, EP might act similarly to some stimulatory factors, such as IGF-1, in a reversible stage of MS.

Keywords: metabolic syndrome, embryonary peptides

Correspondence: G. Mihaescu, Hipocrate 2002-Serv. Trade Company, 6 Prahova Street, Bucharest 1, Romania, e-mail: hip2002@zappmobile.ro

References:

1. Reaven GM. Role of insulin resistance in human diseases. Diabetes 1988; 37: 1595-1599. [CrossRef]
2. Despres JP. Potential contribution of metformin to the management of cardio-vascular risk in patients with abdominal obesity and type 2 diabetes. Diab. Metab. 2003; 29: 6S53-6S59.
3. Hancu N., Roman G., Nita C. et al. Metabolic Syndrome - Practical Approach. Roman. J. Inter, Med. 2004; 42(2): 237-246.
4. Mota M., Panus C., Mota E. et al. Metabolic Syndrome - a multifaced disease. Roman. J. Intern. Med. 2004; 42(2): 247-256.
5. Gruia IM. Olinescu R., Mihaescu G. The modification of oxidative stress in elderly after Orgasel and Humanofort treatment. Infomedica 1997; 11: 40-44.
6. Mihaescu G., Olinescu R., Oancea F., Significant modifications of lipid metabolism in aged persons following the administration of a nutritive supplement. Rom. J. Intern. Med. 2006 - in press.
7. Jaffiel C. Le Syndrome Polymetabolique ou Obesite Maligne. Roum. J. Endocrinol. Metabolism, 2005; 4(3): 14-20.
8. Vaughan CJ., Murphy MB., Buckley BM., Statins do more than lower cholesterol. Lancet l996; 348-352.
9. Serpoi G., Cucu C., Transaminases are significantly increased in patients with metabolic syndrome when compared with obese controls. Acta Endocrinologica 2005; 1(1): 19-30. [CrossRef]
10. Olinescu R., Smith TL., Physiologic Effects of Oxidative Stress: Aging, in: Olinescu R. and Smith TL, Free Radicals in Medicine, Nova Science Publ.Inc. New York, 2002; 120-126.
11. Kummerow FA, Olinescu R., Fleischer L. et al. The relationship of oxidized lipids to coronary artery stenosis. Atherosclerosis, 2000; 149: 181-190.
12. Marcus MA., White GC., Insulin sensitivity and serum triglyceride level in obese white and black women. Metabolism, 1999; 48: 143-149.
13. Czeh MP. New perspectives on the mechanism of insulin action. Recent Progress Hormone Res. 1984; 40: 347-360.
14. Landin WS., Lappas G., Serum IGF-1 in random population sample of men and women. Clin. Endocrinol. Oxford, 1994; 41: 351-357.